Doses studied
Ipamorelin dosage, as it appears in the research — not as a recommendation
The doses, routes, and half-life reported in the literature, in third person and tied to studies. No protocol to follow; the community 'stack' numbers have no human-trial basis.
Read this first
This page describes Ipamorelin dosage the way the studies report it — which species got how much, by which route, for how long — and nothing more. It is not a protocol and contains no recommendation, because there is no validated human dose: ipamorelin is not an approved drug and the popular community regimens have no controlled-trial basis [3]. The numbers worth knowing are these: in rats, bone studies used 18 to 450 micrograms a day under the skin [4]; the one human trial used 0.03 mg/kg into a vein twice daily [3]; and in people, the peptide clears with a half-life of about two hours, producing a single growth-hormone pulse around 40 minutes after a dose [2]. Everything below is study context, in third person.
Doses used in animal and human studies
Across the literature, the studied doses span a wide range by species and goal. In the human pharmacokinetic study, healthy volunteers received single IV infusions of 4.21 to 140.45 nmol/kg over 15 minutes [2]. The human Phase 2 ileus trial used 0.03 mg/kg IV twice daily for up to seven days [3]. In rats, the dose-dependent bone-growth study administered 18, 90, and 450 micrograms a day subcutaneously, split three times daily [4]; a separate bone-mineral study delivered 0.5 mg/kg per day continuously by osmotic minipump for 12 weeks [8]; and the steroid-bone study used 100 micrograms/kg three times daily for three months [7]. The 2024 ferret cachexia study used 1 to 3 mg/kg intraperitoneally [16]. These are research doses in defined models — not human guidance.
Half-life and how long it stays in the system
In healthy human volunteers, ipamorelin's terminal half-life is approximately two hours, with clearance of 0.078 L/h/kg and a steady-state volume of distribution of 0.22 L/kg [2]. The growth-hormone response it triggers is a single discrete pulse peaking near 40 minutes (0.67 h) after dosing, rather than a sustained elevation [2]. In rats, plasma clearance runs roughly five-fold lower than GHRP-6, and 60 to 80 percent of a dose is recovered intact in bile and urine, indicating moderate metabolic stability [5]. The practical reading of a two-hour half-life is that systemic exposure is short-lived; the biological signal is the brief growth-hormone pulse it provokes.
Routes studied
Ipamorelin has been studied by several routes. Intravenous dosing was used in the human PK and clinical-trial work and in some rodent efficacy studies [2] [3]. Subcutaneous injection was the route in the rodent bone and body-composition studies and is also the dominant route in off-label community use [4] [8]. Intranasal delivery reached about 20 percent bioavailability in rodents [5]. Intraperitoneal dosing was used in rodent and ferret efficacy studies [16]. Oral dosing applies only to engineered ipamorelin-derived analogs (about 10 percent in dogs); ipamorelin itself is not orally bioavailable [14].
How much cjc-1295 ipamorelin should i take
<a id="stack-doses"></a>The honest answer to "How much cjc-1295 ipamorelin should i take" is that no validated human dose exists, and this site does not provide one. The CJC-1295 + ipamorelin combination has never been tested in a controlled human trial for any outcome; the only supporting evidence is animal data and the separate single-agent pharmacology of each peptide [15] [3]. Community subcutaneous "stack" protocols circulate widely, but they have no peer-reviewed human dosing basis and must be treated as anecdotal, not recommended [3]. What the literature does establish is mechanism and half-life [1] [2] — not a dose to take.
How to reconstitute cjc-1295 ipamorelin 5mg
<a id="reconstitution"></a>On "How to reconstitute cjc-1295 ipamorelin 5mg": ipamorelin is supplied as a lyophilized (freeze-dried) powder, as the free base or acetate salt, and is reconstituted with bacteriostatic water for research handling [2]. As a peptide it is subject to degradation by heat and repeated freeze-thaw, so reconstituted solution is typically kept refrigerated. These are general peptide-handling observations from the research-supply literature, not a clinical preparation instruction and not a dosing protocol. Because ipamorelin has no approved formulation and research-grade material has unverified purity and identity [3], any handling description here is context only — this digest documents the literature, it does not instruct preparation for use.